Close Menu

This article has been updated from a previous version to add comments from Qiagen's Q1 earnings call.

NEW YORK (GenomeWeb) – Qiagen reported after the close of the market on Tuesday that its first quarter revenues rose 3 percent, bolstered by increases in sales from every business except instruments.

For the three months ended March 31, the company reported revenues of $307.7 million, up from $298.4 million a year ago, and beating the average Wall Street estimate of $306.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.